Coelomic Fluid of Eisenia fetida Ameliorates Cetuximab to Reduce K-Ras and Vimentin Expression through Promoting RUNX3 in an AOM/DSS-Induced Colitis Associated Colon Cancer

Figure 7

CFEF-cetuximab combination therapies were dependent RUNX3 to reduce MMP-2 and MMP-9 percentage in CECs cell. (a) Representative percentage of MMP2 after therapies with cetuximab and various concentrations of CFEF (30, 60, and 120 mg/g BW) in each histogram was shown and analyzed using flow cytometry (FACS Calibur, Becton Dickinson). Cells were gated from double positive cells (K-Ras⁺ and vimentin⁺ populations) and those populations that express RUNX3 were analyzed. Percentage of RUNX3⁺ MMP-2⁺ cell in each quadrant is shown inside the panels. (b) The percentage of RUNX3⁺ MMP-2⁺ cell reduced in CECs on combination therapy groups compared with cetuximab single group. (c) Representative percentage of RUNX3⁺ MMP-9⁺ cell reduced in CECs after combination therapy. Percentage of RUNX3⁺ MMP-9⁺ cell in each quadrant is shown inside the panels. (d) The percentage of RUNX3⁺ MMP-9⁺ cell decreased on combination therapy groups compared with cetuximab single group. Results shown are mean ± SD, with n = 6 replicates in each group. , .

(a)

(b)

(c)

(d)